Clearing the Air on Residual Solvents - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

KeywordLocation
About Search
Clearing the Air on Residual Solvents
USP 9467: Residual Solvents will take effect on July 1, 2008. But does the industry understand these specifications—and is it prepared?


Pharmaceutical Technology


USP ‹467› says that other Class 3 residual solvents should be identified and quantified using methods outlined for Class 1 and Class 2 solvents "with appropriate modifications." But, this may not be easy. "It's not as simple as just running Class 1 and Class 2," says Schumacher. "Companies may find all of a sudden that they are in a position where they need results and they may not have performed the background or have the lab do the background work to develop a method or validate a method to cover their other residual solvents needs. Without a specific monograph saying you can use loss on drying, they are not going to be able to, and [companies] have been used to doing that to cover their bases on Class 3 compounds."

The methods outlined for Class 1 and Class 2 residual solvents can be complex, as some analysts suggest. USP ‹467› outlines three procedures (Procedures A, B, C), prepared differently for water-soluble versus water-insoluble articles, all based on GC-FID.

"The concept here is procedure A is running the work on one specific column, and procedure B is running on an orthogonal column," says Schumacher. "Some compounds will elute better on one versus the other, which laboratories need to give some consideration as well, depending on what compound lists are submitted. And then the C procedure is the true quantitative procedure. A and B are actually semi-quantitative procedures. Their results are acceptable proof negative. If solvent results are below applicable limits, then you don't need to do any further testing. If any solvent exceeds one of the limits, then procedure C applies, which is actually a single-point method of additional spiking of a sample matrix to detemine a quantitative value. You do not need to run procedure A, B, and C in a circumstance where you know what compound list you are looking for. If you have a definiticve compound list and you know what you need to monitor, in theory you can go right to procedure C."

One laboratory has helped its clients understand better the various methodologies by categorizing the list of Class 2 solvents even further, referring to "mix A," "mix B" and "mix C" compounds (1). As Schumacher observes, "The reality is that the prescripted testing only covers a very narrow range of compounds. Only the Class 1 and Class 2 mix A and Class 2 mix B compounds have specific scripted tests," says Schumacher. "Once you run into Class 2 mix C and Class 3, the methodology is not specifically established. So some level of validation will be required," adds Travis Emig, director of pharmaceutical chemistry at Lancaster Laboratories.

One group of Class 2 solvents, however, "are not readily detected by headspace injection conditions," as described in the chapter. As mentioned previously, testing may need to be developed or modified for monitoring Class 3 compounds as well, and sample matrix issues may not allow direct application of ‹467› methodology. For these reasons, USP ‹467› leaves room for manufactures to develop "other appropriate validated procedures," and analysts need only to test for the solvents that are "likely to be present."

Analysts will be the first to make note of the modifications that will help guide the development of these appropriate validated methods."What a lot of what people have found is that there are problems with running <467> verbatim," says Schumacher. "We found problems with running on some headspace systems because specific wording in <467> conflicts with manufacturer design. As 467 is written, procedure A allows the use of a more-narrow bore-diameter column but procedure B does not. I've seen application notes for running <467> that basically have columns that aren't allowed in <467>."

Residual impact

The effect on excipient suppliers. "The best way to control solvents is to control your processes, know your supplier, understand, and try to limit the amount of solvent that you use to what you really need," says Schwarzwalder.


ADVERTISEMENT

post a comment
Your email address will NOT be published.
appears with your comment
read our privacy policy
Note: does not support HTML
All comments submitted are subject to review, and may be delayed before posting. We reserve the right not to post comments.
LCGC E-mail Newsletters
Subscribe:Check the box next to each newsletter you wish to subscribe for:
| Weekly
| Monthly
| Monthly | Weekly
 Name:
 E-mail:

Survey
At this month's AAPS Annual Meeting & Exposition, several graduate students were awarded as young innovators. What are your thoughts on innovation and the next generation?
We need more young innovators and more students enrolling in pharma science programs
Our industry has just the right mix of young and old to keep innovation going
Age is irrelevant when it comes to innovation
We need more young innovators and more students enrolling in pharma science programs
25%
Our industry has just the right mix of young and old to keep innovation going
16%
Age is irrelevant when it comes to innovation
59%
View Results
Jim MillerOutsourcing OutlookJim Miller Facing Reality
Patricia Van ArnumIngredients InsiderPatricia Van Arnum Advancing Chiral Chemistry in API Synthesis
Faiz kermaniSpotlightFaiz Kermani Demographic time bomb
Rx-360 Takes on Europe, Talks to PharmTech in Podcast Series
Sanctions, Not Barcodes
Vaccines Finding Their Way in Novel Applications
Genzyme’s Friday the 13th
DTCA: Beneficial or Harmful?
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here